Clinical practice aromatase inhibitors: Upfront, switch or extended?

Greil, R, Jonat, W, Maass, N, Kaufmann, M, Ortmann, O, Possinger, K, Steger, G BREAST CARE. 2006, 1(1): 37-43.

Diffuse large B-cell lymphoma as a second, clonally unrelated lymphoproliferative disease in a patient with IgM monoclonal gammopathy of undetermined significance (MGUS) and concomitant polycythemia vera rubra.

Mian M, Psenak O, Greil R, Fiegl M, Tzankov A. Leuk Lymphoma. 2006 May,47(5):940-3. No abstract available.

Planned first efficacy and safety analysis of de-intensified induction with fludarabine, cyclophosphamide plus rituximab (FCR) followed by fludarabine plus rituximab (FR) and remission maintenance therapy with rituximab in previously untreated B-chronic lymphocytic leukemia (B-CLL): The chairos study

Egle, A, Weiss, L, Russ, G, Thoedtmann, R, Pleyer, L, Gastl, G, Thaler, J, Petzer, A, Tinhofer, I, Greil, R BLOOD. 2007, 110(11): 609A-609A.

A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer.

Schippinger W, Samonigg H, Schaberl-Moser R, Greil R, Thödtmann R, Tschmelitsch J, Jagoditsch M, Steger GG, Jakesz R, Herbst F, Hofbauer F, Rabl H, Wohlmuth P, Gnant M, Thaler J Br J Cancer. 2007 Oct 22,97(8):1021-7. Epub 2007 Sep 25.

[Expert recommendations 2006 on the rationale for second-line therapy for non-small cell bronchial neoplasms].

Hilbe W, Aigner K, Dittrich C, Eckmayr J, Fiegl M, Flicker M, Forstner B, Greil R, Jamnig H, Krajnik G, Lang A, Mohn-Staudner A, Schinko H, Studnicka M, Pirker R, Ploner F, Rothmund J, Schiller L, Zabernigg A, Zöchbauer-Müller S. Wien Klin Wochenschr. 2007,119(7-8):259-66.

Is it time to consider neoadjuvant treatment as the standard of care in oesophageal cancer?

Greil R, Stein HJ. Lancet Oncol. 2007 Mar,8(3):189-90.

Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.

Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, Mlineritsch B, Tausch C, Stierer M, Hofbauer F, Renner K, Dadak C, RГјcklinger E, Samonigg H J Natl Cancer Inst. 2007 Dec 19,99(24):1845-53. Epub 2007 Dec 11. Erratum in: J Natl Cancer Inst. 2008 Feb 6,100(3):226.

Massive infiltration of bone marrow in colon carcinoma after treatment with activated protein C.

Pleyer L, Went P, Russ G, Prinz E, Faber V, Röwert HJ, Karlbauer R, Greil R. Wien Klin Wochenschr. 2007,119(7-8):254-8.

Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.

Porschen R, Arkenau HT, Kubicka S, Greil R, Seufferlein T, Freier W, Kretzschmar A, Graeven U, Grothey A, Hinke A, Schmiegel W, Schmoll HJ J Clin Oncol. 2007 Sep 20,25(27):4217-23. Epub 2007 Jun 4.

Hematopoietic growth factors: ESMO recommendations for the application.

ESMO Guidelines Working Group, Greil R, Psenak O. Ann Oncol. 2007 Apr,18 Suppl 2:ii89-91.